INT8916

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 1991
Last Reported 2010
Negated 8
Speculated 7
Reported most in Body
Documents 45
Total Number 52
Disease Relevance 13.06
Pain Relevance 5.81

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Igf1) extracellular region (Igf1)
Anatomy Link Frequency
plasma 6
brain 3
molar 2
cardiac myocytes 1
reproductive organ 1
Igf1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Nerve growth factor 16 100.00 Very High Very High Very High
qutenza 13 100.00 Very High Very High Very High
anesthesia 23 99.88 Very High Very High Very High
Opioid 3 99.46 Very High Very High Very High
Clonidine 10 98.88 Very High Very High Very High
Calcitonin gene-related peptide 13 98.84 Very High Very High Very High
opiate 4 98.82 Very High Very High Very High
agonist 104 97.84 Very High Very High Very High
halothane 3 97.20 Very High Very High Very High
cytokine 59 95.40 Very High Very High Very High
Disease Link Frequency Relevance Heat
Precocious Puberty 14 100.00 Very High Very High Very High
Atherosclerosis 50 99.56 Very High Very High Very High
Hypertension 11 99.28 Very High Very High Very High
Urological Neuroanatomy 20 99.26 Very High Very High Very High
Acromegaly 263 99.08 Very High Very High Very High
Alopecia 3 98.00 Very High Very High Very High
Death 30 97.48 Very High Very High Very High
Injury 39 97.24 Very High Very High Very High
Sepsis 37 97.00 Very High Very High Very High
Hypogonadotropic Hypogonadism 6 96.52 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Effect of capsaicin on plasma and tissue levels of insulin-like growth factor-I in spontaneously hypertensive rats.
Regulation (Effect) of insulin-like growth factor-I in plasma associated with qutenza and hypertension
1) Confidence 0.60 Published 2008 Journal Growth Horm. IGF Res. Section Title Doc Link 17693108 Disease Relevance 0.19 Pain Relevance 0.34
In conclusion, this study found that self- or partner- administration of lanreotide was generally well tolerated and associated with control of IGF-1 and GH levels in many lanreotide-naïve patients with acromegaly.
Regulation (control) of IGF-1 associated with acromegaly
2) Confidence 0.60 Published 2009 Journal Pituitary Section Body Doc Link PMC2855862 Disease Relevance 0.45 Pain Relevance 0.04
Both IGF-1 and GH were controlled in 73.1% of switch and 30.4% of “other” patients.
Regulation (controlled) of IGF-1
3) Confidence 0.60 Published 2009 Journal Pituitary Section Abstract Doc Link PMC2855862 Disease Relevance 0.13 Pain Relevance 0.04
In this study, we investigated the effects of exercise during pregnancy on maternal plasma levels of GH, IGF-I and IGFBP-3 and on fetal development.
Spec (investigated) Regulation (effects) of IGF-I in plasma
4) Confidence 0.59 Published 2006 Journal Tohoku J. Exp. Med. Section Abstract Doc Link 16340176 Disease Relevance 0.09 Pain Relevance 0.06
The goal of this study was to determine the effect of molecular variants of the IGF-1 P1 promoter on IGF-1 serum levels and to determine the impact of IGF-1 levels on the severity of coronary atherosclerosis.
Spec (determine) Regulation (effect) of IGF-1 associated with atherosclerosis
5) Confidence 0.58 Published 2010 Journal Protein J Section Abstract Doc Link PMC2951508 Disease Relevance 0.26 Pain Relevance 0.07
To determine whether systemic and/or intraovarian concentrations of insulin-like growth factor-I (IGF-I) are affected by short-term fasting, 24 heifers were blocked by weight and, within block, were assigned to one of three treatments: fasted for 0 h (controls; n = 8), fasted for 24 h (n = 8), or fasted for 48 h (n = 8).
Spec (whether) Regulation (affected) of insulin-like growth factor-I
6) Confidence 0.47 Published 1992 Journal Biol. Reprod. Section Abstract Doc Link 1591347 Disease Relevance 0 Pain Relevance 0.07
Systemic but not intraovarian concentrations of insulin-like growth factor-I are affected by short-term fasting.
Regulation (affected) of insulin-like growth factor-I
7) Confidence 0.47 Published 1992 Journal Biol. Reprod. Section Title Doc Link 1591347 Disease Relevance 0.06 Pain Relevance 0.08
IGF-1 infusion did not change the heart rate in control rats but decreased it in CGRP-deficient rats.
Neg (not) Regulation (change) of IGF-1 in heart associated with calcitonin gene-related peptide
8) Confidence 0.44 Published 2002 Journal Endocrine Section Abstract Doc Link 12588046 Disease Relevance 0.08 Pain Relevance 0.56
Because both IGFBP-1 and 2 have been proposed as regulators of IGF transport, we directly determined their distribution and elimination characteristics in rats. 125I-IGFBP-1 and 2 were injected into anesthetized normal rats.
Regulation (regulators) of IGF
9) Confidence 0.44 Published 1992 Journal Endocrinology Section Abstract Doc Link 1382964 Disease Relevance 0 Pain Relevance 0
The second group included parous rats that did not receive any IGF-I treatment.
Neg (not) Regulation (receive) of IGF-I
10) Confidence 0.42 Published 2004 Journal Breast Cancer Res Section Body Doc Link PMC468665 Disease Relevance 0.15 Pain Relevance 0
The third group included age-matched virgin control animals, which also did not receive any IGF-I treatment.
Neg (not) Regulation (receive) of IGF-I
11) Confidence 0.42 Published 2004 Journal Breast Cancer Res Section Body Doc Link PMC468665 Disease Relevance 0.14 Pain Relevance 0
These conflicting results leave the role of IGF-1 levels in coronary atherosclerosis an unresolved question.
Regulation (role) of IGF-1 associated with atherosclerosis
12) Confidence 0.42 Published 2010 Journal Protein J Section Body Doc Link PMC2951508 Disease Relevance 0.66 Pain Relevance 0
The goal of this study was to determine the effect of molecular variants of the IGF-1 P1 promoter on IGF-1 serum levels and to determine the impact of IGF-1 levels on the severity of coronary atherosclerosis.
Spec (determine) Regulation (impact) of IGF-1 associated with atherosclerosis
13) Confidence 0.42 Published 2010 Journal Protein J Section Abstract Doc Link PMC2951508 Disease Relevance 0.26 Pain Relevance 0.07
The MCL was chosen as a model system since this ligament, unlike tendons, has no muscular attachment and therefore possible alterations in muscle strength after IGF-I and/or GH treatment do not impose substantial differential loads on the ligament during hindlimb unloading.
Spec (possible) Regulation (alterations) of IGF-I in hindlimb
14) Confidence 0.42 Published 2007 Journal BMC Physiol Section Body Doc Link PMC1851714 Disease Relevance 0.31 Pain Relevance 0
Effects of capsaicin and isoflavone on blood pressure and serum levels of insulin-like growth factor-I in normotensive and hypertensive volunteers with alopecia.
Regulation (Effects) of insulin-like growth factor-I in blood associated with qutenza, hypertension and alopecia
15) Confidence 0.31 Published 2009 Journal Biosci. Biotechnol. Biochem. Section Title Doc Link 19502719 Disease Relevance 0.65 Pain Relevance 0.71
The biochemical control of glucose-suppressed GH and IGF-1 were determined at weeks 0 and 24 as: normal IGF-1 and GH <1 ?
Regulation (control) of IGF-1
16) Confidence 0.26 Published 2009 Journal Pituitary Section Body Doc Link PMC2855862 Disease Relevance 0.20 Pain Relevance 0.51
Self- or partner-administration of lanreotide was associated with both IGF-1 and GH control in many patients with acromegaly (73.1% of switch patients and 30.4% of “other” patients at week 24 or early termination versus 63.3% and 4.0% at week 0, respectively; Table 2).
Regulation (control) of IGF-1 associated with acromegaly
17) Confidence 0.26 Published 2009 Journal Pituitary Section Body Doc Link PMC2855862 Disease Relevance 0.18 Pain Relevance 0
A previous study also found that patients who were on lanreotide for at least 4 months and who received injections by a health care professional were able to successfully switch to self- or partner-administer lanreotide while maintaining GH and IGF-1 control [9].
Regulation (control) of IGF-1
18) Confidence 0.26 Published 2009 Journal Pituitary Section Body Doc Link PMC2855862 Disease Relevance 0 Pain Relevance 0
As one might expect, the duration of acromegaly was longer in switch than in “other” patients, since they were previously on a fixed dose of SSA, and their IGF-1 and GH control was maintained with lanreotide treatment in this study.
Regulation (control) of IGF-1 associated with acromegaly
19) Confidence 0.26 Published 2009 Journal Pituitary Section Body Doc Link PMC2855862 Disease Relevance 0.23 Pain Relevance 0
Self- or partner-administration of lanreotide is generally well tolerated and associated with IGF-1 and GH control in many lanreotide-naïve patients with acromegaly.



Regulation (control) of IGF-1 associated with acromegaly
20) Confidence 0.26 Published 2009 Journal Pituitary Section Abstract Doc Link PMC2855862 Disease Relevance 0.16 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox